Terms: = Prostate cancer AND TET2, Q6N021, MGC125715, KIAA1546, FLJ20032, ENSG00000168769, 54790 AND Prognosis
3 results:
1. Differences in Genomic Alterations Between Brain Metastases and Primary Tumors.
Dono A; Takayasu T; Yan Y; Bundrant BE; Arevalo O; Lopez-Garcia CA; Esquenazi Y; Ballester LY
Neurosurgery; 2021 Feb; 88(3):592-602. PubMed ID: 33369669
[TBL] [Abstract] [Full Text] [Related]
2. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with prostate cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract] [Full Text] [Related]
3. The CpG island methylator phenotype: what's in a name?
Hughes LA; Melotte V; de Schrijver J; de Maat M; Smit VT; Bovée JV; French PJ; van den Brandt PA; Schouten LJ; de Meyer T; van Criekinge W; Ahuja N; Herman JG; Weijenberg MP; van Engeland M
Cancer Res; 2013 Oct; 73(19):5858-68. PubMed ID: 23801749
[TBL] [Abstract] [Full Text] [Related]
